Potential interest of anti-ischemic agents for limiting cyclosporin A nephrotoxicity

International Journal of Clinical Pharmacology Research

Volumn 17, Issue 4, 1997, Pages 133-142

  Simon, N ^a   Tillement, J P ^a   Albengres, E ^a   Jaber, K ^b   Hestin, D ^c   Roux, F ^b   Olivier, P ^c   D'Athis, Ph ^a   Kessler, M ^c   Berland, Y ^b   Crevat, A ^b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; CYCLOSPORIN A; OXIDIZING AGENT; TRIMETAZIDINE;

ARTICLE; DRUG EFFECT; HUMAN; IMMUNOMODULATION; MEMBRANE PERMEABILITY; MITOCHONDRION; NEPHROTOXICITY; NONHUMAN;

ADENOSINE TRIPHOSPHATE; CALCIUM; CREATININE; CYCLOSPORINE; HUMANS; KIDNEY; MITOCHONDRIA; MYOCARDIAL ISCHEMIA; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 7844240482     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Beveridge T. Clinical Transplantation - Overview. In: Borel J.F. (Ed.) "Ciclosporin". Karger, Basel, 1986, pp 269-92.
2. Kahan B.D. Cyclosporine. N Engl J Med, 321, 1725, 1989.
3. Gjertson D.W., Cecka J.M., Terasak: P.I. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation, 60, 1384, 1995.
4. Bennett W.M., DeMattos A., Meyer M.M., Andoh T., Barry J.M. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int., 50, 1089, 1996.
5. McNally P.G., Feehally J. Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations. Nephrol. Dial. Transplant., 7, 791, 1992.
6. Mihatsch MJ., Thiel G., Spichtin H.P., et al. Morphological findings in kidney transplants after treatment with cyclosporine. Transplant Proc., 15, 2821, 1983.
7. Murray B.M., Paller M.S. Beneficial effect of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin. Nephrol., 25, S37, 1986.
8. Hermanesson K., Larson M., Kallskog O., Wolgast M. Influence of renal nerve activity on arteriolar resistance, ultrafiltration dynamics and fluid reabsorption. Pflügers Arch., 389, 85, 1981.
9. Kon V., Ichikawa I. Effector loci for renal nerve control of cortical microcirculation. Am J Physiol., 245, F545, 1983.
10. Bantle J.P., Bourdreau R.J., Ferris T.F, Suppression of plasma renin activity by cyclosporine. Am. J. Med., 83, 59, 1987.
11. Pestana M., Vieira-Coelho M.A., Pinto-do-O P.C., Fernandes M.H., Soares-da-Silva P. Assessment of renal dopaminergic system activity during cyclosporine A administration in the Rat. Br. J. Pharmacol., 115, 1349, 1995.
12. Brooks D.P., Drutz D.J., Ruffolo R.R. Prevention and complete reversal of cyclosporine A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam. J. Pharmacol. Exp. Ther. 254, 375, 1990.
13. Remuzzi G., Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am. J. Kidney Dis., 13, 261, 1989.
14. Coffman T.M., Smith S.R., Creech E.A., et al. The thromboxane synthetase inhibitor CGS 13080 improves renal allograft function in patients taking cyclosporine A. Kidney Int., 37, 604A, 1990.
15. Kim H.J., Kwak J.Y. Effects of Misoprostol on renal function and plasma endothelin-1 levels during early postoperative stage of living donor renal transplant recipients. Transplant Proc., 28, 1207, 1996.
16. Langman L.J., Yatscoff R.W. Comparison of the effects of cyclosporin G (OG37-325), cyclosporin A, and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cell lines. Ther Drug Monit., 16, 450, 1994.
17. Bunchman T.E., Brookshire C.A. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells J. Clin. Invest., 88, 310, 1991.
18. Kon V., Badr K.F. Biological actions and pathophysiologic significance of endothelin in the kidney. Kidney Int., 40, 1, 1991.
19. Kon V., Hunley T.E., Fogo A. Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation, 60, 89, 1995.
20. Brooks D.P., Contino L.C. Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670. Eur. J. Pharmacol., 294, 571, 1995.
21. Gardner M.P., Houghton D.C., Andoh T.F., Lindsley J., Bennett W.M. Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition. Transplantation, 61, 1506, 1996.
22. Bobadilla N.A., Tapia E., Franco M., et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int., 37, 604A, 1994.
23. Stephan D., Billing A., Krieger J.P., et al. Endothelium-dependent relaxation in the isolated rat kidney: impairment by cyclosporine A. J Cardiovasc Pharmacol, 26, 859, 1995.
24. Mihatsch M.J., Ryffel B., Gudat F. Differential diagnosis between rejection and cyclosporine toxicity. Kidney Int., 48 (Suppl. 52), 63, 1995.
25. Shehata M., Cope G.H., Johnson T.S., Raftery A.T., El Nahas A.M. Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int., 48, 1487 1995.
26. Young B.A., Burdirann E.A., Johnson R.J., et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int., 48, 439, 1995
27. Shihab F.S., Andoh T.F., Tanner A.M., et al. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int., 49, 1141, 1996.
28. Pfeilschifter J, Cyclosporin A augments vasoconstrictor-induced rise in intracellular tree calcium in rat renal mesangial cells. Biochem. Pharmacol., 37, 4205, 1988.
29. Rego A., Vargas P., Suarez K.R., Foegh M.L., Ramwell P.W. Mechanism of cyclosporin potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: role of extracellular calcium. J. Pharmacol. Exp. Then, 254, 799, 1990.
30. 2+ release in permeabilized human neutrophils induced by cyclosporin, Nephron, 56, 30, 1990
31. Kirk A.J.B., Omar I., Dark J.H. Long-term improvement in renal function using nifedipine in cyclosporine-associated hypertension. Transplantation 50, 1061, 1990.
32. Chagnac A., Zevin D., Ori Y., Korzets A., Hirsh J., Levi J. The effect of high-dose nifedipine on renal hemodynamics of cyclosporine-troated renal allograft recipients. Transplantation, 53, 766, 1992.
33. McCrea J., Fraruos G.F., Burke J.F., Michael H.J. The beneficial effects of isradipine on renal hemodynamics in cyclposporine-treated renal transplant recipients. Transplantation., 55, 672, 1993.
34. Ruggenenti P., Perico N., Mosconi L., et al. Calcium channel blockers protect transplant patients from cyclosporine- induced daily renal hypoperfusion Kidney Int., 43, 706, 1993.
35. Gallego M.J., Lopez Farré A., Resco A., et al. Blockade of endothelium-dependent responses in conscious rats by cyclosporine A: effect of L-arginine Am. J. Physiol. 264, H708, 1993.
36. Shimokawa H., Vanhoutte P.M. Dietary omega 3 fatty acids and endothellium-dependent relaxations in porcine coronary arteries. Am. J. Physiol. 256, H968, 1989.
37. Berthoux F.C., Guerin C., Burgard G., Berthoux P., Alamartine E. One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation. Transplant Proc., 24, 2578, 1992.
38. Paulson D.J., Traxler J., Schmidt P., Noonar J., Shug A.L. Protection of the ischeme myocardium by L-propionylcarnitine: effects on the recovery of cardiac output alter ischemia and reperfusion, carnitine transport, and fatty acid oxidation. Carciovasc. Res., 20, 536, 1986.
39. Bertelli A., Giovanni L., Palla R., Migliori M., Panichi V., Andreini B. Protective effect of L-propionylcamitine on cyclosporine-induced nephrotoxicity. Drugs Exptl. Clin. Res., 21, 221. 1995.
40. Shaw L.M., Kaplan B., Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin. Chem., 42, 1316, 1996.
41. Schrier R.W., Arnold P.E., Van Putten V.J., Burke T.J. Cellular calcium in ischemic acute renal failure: role of calcium entry blockers. Kidney Int., 32, 313, 1987.
42. Salducci M.D., Chauvet-Monges A.M., Berland Y., Dussol B., Elsen R., Crevat A. The restoration of ATP synthesis may explain the protective effect of calcium antagonists against cyclosporine A. Life Sciences, 50, 2053-2058, 1992.
43. Hay R., Tammi K., Ryffel B., Mihatsch M.J. Alterations in molecular structure of renal mitochondria associated with cyclosporine A treatment. Clin. Nephrol., 25, S23, 1986.
44. Harpey C., Clauser P., Labrd C., Freyria J.L., Poirier J.P. Trimetazidine, A cellular anti-ischemic agent. Cardiovascular Drug Reviews, 6, 292, 1388.
45. Salducci M.D., Chauvet-Monges A.M., Tillement J.P. Trimetazdine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J. Pharmacol. Exp. Ther., 277, 417, 1996.
46. 2+-dependent mitochondrial swelling. Fundam. Clin. Pharmacol., 11, 440, 1997
47. Albengres E., Tillemont J.P., d'Athis P., Salducci D., Chauvet-Monge A.M., Crevat A, Lack of pharmacodynamic interaction between trimetazidine and cyclosporin A in human lymphoproliferative and mouse delayed hypersensitivity response models. Fundam. Clin. Pharmacol., 10, 264, 1996.
48. Simon N., Brunet P, Roumenov D., et al. The effects of trimetazidine-cyclosponn A coadministration on interleukin 2, soluble interleukin 2-receptors, and cyclosporin A blood levels in renal transplant patients. Thérap e, 50, S498, 1995.
49. 2+ and oxidant stress. Eur. J. Biochem. 238, 166, 1996.
50. Lo Russo A., Passaquin A.C., Andre P., Skutella M., Rüegg U.T. Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosupressive activity. Br. J. Pharmacol., 118, 885, 1996.
51. Creagh T., Lanigan D., Dolan J., Tormey W., Walshe J.J., Bouchier-Hayes D. Pharmacological manipulation of acute cyclosporin ischemic renal injury with trimetazidine. J. Urol., 149, 915, 1993.